Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
483.00
-15.73 (-3.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
52
53
Next >
Better Growth Stock: Archer Aviation or Prime Medicine?
December 19, 2023
Which of these innovation-themed growth stocks is the better buy?
Via
The Motley Fool
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
December 18, 2023
It's important to choose companies involved in trends that have long-term potential.
Via
The Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
December 16, 2023
The benefits from its first drug launch will trickle in slowly, at least at first.
Via
The Motley Fool
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
December 16, 2023
This biotech could have more winners on the way.
Via
The Motley Fool
After This Landmark Win, Is CRISPR Therapeutics a Buy?
December 15, 2023
CRISPR Therapeutics stock already has advanced in the double digits this year.
Via
The Motley Fool
Why Vertex Stock Is Soaring Today
December 13, 2023
The drugmaker's non-opioid painkiller is showing promise in a select set of patients.
Via
The Motley Fool
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
December 13, 2023
Via
Investor Brand Network
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review
December 15, 2023
The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030
December 14, 2023
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy.
Via
InvestorPlace
Topics
ETFs
The Latest Analyst Ratings for Vertex Pharmaceuticals
December 11, 2023
Via
Benzinga
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 13, 2023
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700...
Via
Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
December 13, 2023
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial
December 13, 2023
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage
Via
Benzinga
Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
December 13, 2023
The company tested an alternative to opioids and NSAIDs in patients with diabetic peripheral neuropathy.
Via
Investor's Business Daily
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
December 13, 2023
The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks.
Via
InvestorPlace
Exposures
COVID-19
1 Biotech Stock That Could Be the Next Amgen
December 13, 2023
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
Via
The Motley Fool
Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative
December 13, 2023
Vertex stock spiked early Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.
Via
Investor's Business Daily
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
December 13, 2023
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.
Via
The Motley Fool
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
December 12, 2023
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.
Via
Investor's Business Daily
Exposures
Product Safety
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Why CRISPR Stock Keeps Falling
December 11, 2023
CRISPR just scored its first FDA victory -- but profits remain years away.
Via
The Motley Fool
Exposures
Product Safety
Bull Of The Day: Crispr Therapeutics
December 11, 2023
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...
Via
Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
December 11, 2023
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.